Ginsenoside Rb1 Lessens Gastric Precancerous Lesions by Interfering With β-Catenin/TCF4 Interaction

Zeng, Jinhao; Ma, Xiao; Zhao, Ziyi; Chen, Yu; Wang, Jundong; Hao, Yanwei; Yu, Jun-Rong; Zeng, Zhongzhen; Chen, Nianzhi; Zhao, Maoyuan; Tang, Jian-Yuan; Gong, Daoyin

doi:10.3389/fphar.2021.682713

Cited by 16 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rb1 is a kind of dammarane triterpenoid saponin, which is considered to be one of the most important active components in ginseng and a primary component playing a pharmacological role. Rb1 has many bene cial effects on the human body, including cardiovascular and central nervous system activities, anti-diabetic, and anti-tumor activities (27)(28)(29)(30). Rb1 can reduce oxidative stress, inhibit in ammation, downregulate MDA, inhibit ROS, and promote GSH expression, due to its bene cial characteristics.…”

Section: Discussionmentioning

confidence: 99%

Ginsenoside Rb1 ameliorates renal tubular epithelial cells ferroptosis in AKI

Deng

Tao³

et al. 2022

Preprint

View full text Add to dashboard Cite

Acute kidney injury (AKI) is mainly caused by ischemia-reperfusion (I/R), with high clinical mortality since there is a lack of definite and effective drug intervention except for renal replacement therapy. Previous research emphasized that ferroptosis is the pivotal process in I/R injury of renal. Ginsenoside Rb1 is a chemical compound belonging to the ginsenoside family and has been proved to have benefits for kidney diseases, but its specific mechanism in AKI is uncovered. Here we discovered Rb1 could mitigate ferroptosis in renal tubular epithelial cells of AKI animals. Mechanically, Rb1 significantly inhibited oxidative stress including promotion of GSH, reduction of malondialdehyde (MDA) and reactive oxygen species (ROS), also reduced inflammatory response, then relieved renal injury in I/R mice. RSL3, the inhibitor of GPX4, or Erastin, the inhibitor of SLC7A11, could induce ferroptosis and eliminate the protective effect of Rb1. Also, a ferroptosis inhibitor or ROS scavenger could simulate the protective effect of Rb1 on renal tubular epithelial cells. In conclusion, we confirmed that Rb1 promotes GSH synthesis by preventing oxidative stress, upregulating the expression of GPX4 and SLC7A11, and ultimately scavengers of ROS or MDA, and reduces the occurrence of ferroptosis in renal tubular epithelial cells. Rb1 has potential benefits for AKI patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Ginsenoside Rb1 ameliorates renal tubular epithelial cells ferroptosis in AKI

Deng

Tao³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…It is widely used for the management of GPL in clinical practice. Zeng et al [ 33 ] found that Weipixiao can inhibit cell proliferation and induce apoptosis by inhibiting abnormal activation of the Wnt/β-catenin signaling pathway, while GRb1 can inhibit β-catenin protein expression. Downstream targets, such as c-myc, Cyclin D1, Lgr5, MMP-7, and Birc5, in this pathway are inhibited.…”

Section: Mechanism Of Tcm In the Treatment Of Gplmentioning

confidence: 99%

“…For example, WFC can increase the secretion of pepsin by inhibiting the MAPK signaling pathway, thereby regulating the weight of rats with GPL and improving histopathological changes in the gastric mucosa[ 32 ]. Another study showed that Ginsenoside Rb1 (GRb1), which is contained in WFC, can prevent the occurrence and progression of GPLs by reducing the protein expression and nuclear translocation of β-catenin, interfering with the interaction of β-catenin/TCF4, and inhibiting the transcriptional activity of downstream genes, including c-myc, Cyclin D1 and Birc5[ 33 ]. Therefore, it is important to study the effect of TCM on GPL to improve the clinical efficacy and transformation of drug research and development (R&D).…”

Section: Introductionmentioning

confidence: 99%

Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review

Zhong¹,

Wang²,

Hao³

et al. 2023

World J Gastrointest Oncol

View full text Add to dashboard Cite

Gastric cancer (GC) is a common gastrointestinal tumor. Gastric precancerous lesions (GPL) are the last pathological stage before normal gastric mucosa transforms into GC. However, preventing the transformation from GPL to GC remains a challenge. Traditional Chinese medicine (TCM) has been used to treat gastric disease for millennia. A series of TCM formulas and active compounds have shown therapeutic effects in both GC and GPL. This article reviews recent progress on the herbal drugs and pharmacological mechanisms of TCM in preventing the transformation from GPL to GC, especially focusing on anti-inflammatory, anti-angiogenesis, proliferation, and apoptosis. This review may provide a meaningful reference for the prevention of the transformation from GPL to GC using TCM.

show abstract

“…β-linked protein upregulation and nuclear translocation are significantly associated with advanced gastric precancerous lesions (GPL). Zeng et al ( Zeng et al, 2021 ) observed that GRb1 reduced the protein expression and nuclear translocation of β-catenin, interfered with β-catenin/TCF4 interactions, and prevented the development and progression of GPL.…”

Section: Prevention Of Precancerous Lesions By the Active Ingredients...mentioning

confidence: 99%

Research progress of ginseng in the treatment of gastrointestinal cancers

Song²,

Shi³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer has become one of the major causes of human death. Several anticancer drugs are available; howeve their use and efficacy are limited by the toxic side effects and drug resistance caused by their continuous application. Many natural products have antitumor effects with low toxicity and fewer adverse effects. Moreover, they play an important role in enhancing the cytotoxicity of chemotherapeutic agents, reducing toxic side effects, and reversing chemoresistance. Consequently, natural drugs are being applied as potential therapeutic options in the field of antitumor treatment. As natural medicinal plants, some components of ginseng have been shown to have excellent efficacy and a good safety profile for cancer treatment. The pharmacological activities and possible mechanisms of action of ginseng have been identified. Its broad range of pharmacological activities includes antitumor, antibacterial, anti-inflammatory, antioxidant, anti-stress, anti-fibrotic, central nervous system modulating, cardioprotective, and immune-enhancing effects. Numerous studies have also shown that throuth multiple pathways, ginseng and its active ingredients exert antitumor effects on gastrointestinal (GI) tract tumors, such as esophageal, gastric, colorectal, liver, and pancreatic cancers. Herein, we introduced the main components of ginseng, including ginsenosides, polysaccharides, and sterols, etc., and reviewed the mechanism of action and research progress of ginseng in the treatment of various GI tumors. Futhermore, the pathways of action of the main components of ginseng are discussed in depth to promote the clinical development and application of ginseng in the field of anti-GI tumors.

show abstract

Ginsenoside Rb1 Lessens Gastric Precancerous Lesions by Interfering With β-Catenin/TCF4 Interaction

Cited by 16 publications

References 36 publications

Ginsenoside Rb1 ameliorates renal tubular epithelial cells ferroptosis in AKI

Ginsenoside Rb1 ameliorates renal tubular epithelial cells ferroptosis in AKI

Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review

Research progress of ginseng in the treatment of gastrointestinal cancers

Contact Info

Product

Resources

About